M Maral Mouradian

List of Publications by Year
in descending order

117 papers	10,211 citations	34016 52 h-index	34900 98 g-index
119 all docs	119 docs citations	119 times ranked	11471 citing authors

#	Article	IF	Citations
1	The Role of Oxidative Stress in Parkinson's Disease. Journal of Parkinson's Disease, 2013, 3, 461-491.	1.5	1,218
2	Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease. Science, 2002, 296, 2238-2243.	6.0	638
3	Repression of Î±-synuclein expression and toxicity by microRNA-7. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13052-13057.	3.3	575
4	Degradation of Î±-Synuclein by Proteasome. Journal of Biological Chemistry, 1999, 274, 33855-33858.	1.6	376
5	Aggresomes Formed by Î±-Synuclein and Synphilin-1 Are Cytoprotective. Journal of Biological Chemistry, 2004, 279, 4625-4631.	1.6	356
6	Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9691-9696.	3.3	299
7	Mitochondrial localization of DJâ€1 leads to enhanced neuroprotection. Journal of Neuroscience Research, 2009, 87, 123-129.	1.3	270
8	Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Annals of Neurology, 1990, 27, 18-23.	2.8	259
9	Tissue transglutaminase-induced aggregation of Â-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2047-2052.	3.3	237
10	Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology, 2002, 58, 179-185.	1.5	230
11	Human Î±-Synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neuroscience Letters, 2002, 320, 146-150.	1.0	229
12	Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases. Journal of Neurochemistry, 2001, 78, 374-383.	2.1	194
13	Enhanced vulnerability to oxidative stress by Î±-synuclein mutations and C-terminal truncation. Neuroscience, 2000, 97, 279-284.	1.1	189
14	MicroRNAs in neurodegenerative diseases and their therapeutic potential. , 2012, 133, 142-150.		186
15	Interaction between Mutant Ataxin-1 and PQBP-1 Affects Transcription and Cell Death. Neuron, 2002, 34, 701-713.	3.8	182
16	DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway. Human Molecular Genetics, 2012, 21, 3013-3024.	1.4	169
17	Enhanced Phosphatase Activity Attenuates Î±-Synucleinopathy in a Mouse Model. Journal of Neuroscience, 2011, 31, 6963-6971.	1.7	163
18	PQBP-1, a novel polyglutamine tract-binding protein, inhibits transcription activation by Brn-2 and affects cell survival. Human Molecular Genetics, 1999, 8, 977-987.	1.4	159

#	Article	IF	Citations
19	MicroRNAs in Parkinson's disease. Neurobiology of Disease, 2012, 46, 279-284.	2.1	142
20	Targeting of marrow-derived astrocytes to the ischemic brain. NeuroReport, 1999, 10, 1289-1292.	0.6	135
21	Inhibition of miRâ€34b and miRâ€34c enhances Î±â€synuclein expression in Parkinson's disease. FEBS Letters, 2015, 589, 319-325.	1.3	134
22	Parkin Accumulation in Aggresomes Due to Proteasome Impairment. Journal of Biological Chemistry, 2002, 277, 47870-47877.	1.6	132
23	Selective D-1 dopamine receptor agonist treatment of parkinson's disease. Journal of Neural Transmission, 1987, 68, 41-50.	1.4	126
24	Regulation of striatal dopamine receptors by estrogen. Synapse, 1999, 34, 222-227.	0.6	95
25	Continuous Transdermal Dopaminergic Stimulation in Advanced Parkinson's Disease. Clinical Neuropharmacology, 2001, 24, 163-169.	0.2	89
26	Cytoprotective mechanisms of DJ-1 against oxidative stress through modulating ERK1/2 and ASK1 signal transduction. Redox Biology, 2018, 14, 211-217.	3.9	89
27	Casein Kinase II-mediated Phosphorylation Regulates Î±-Synuclein/Synphilin-1 Interaction and Inclusion Body Formation. Journal of Biological Chemistry, 2004, 279, 6834-6839.	1.6	87
28	Striatal Overexpression of Î”FosB Reproduces Chronic Levodopa-Induced Involuntary Movements. Journal of Neuroscience, 2010, 30, 7335-7343.	1.7	86
29	Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neuroscience and Biobehavioral Reviews, 1997, 21, 447-453.	2.9	85
30	MicroRNA-7 Protects against 1-Methyl-4-Phenylpyridinium-Induced Cell Death by Targeting RelA. Journal of Neuroscience, 2014, 34, 12725-12737.	1.7	85
31	Proteasome inhibition induces Î±-synuclein SUMOylation and aggregate formation. Journal of the Neurological Sciences, 2011, 307, 157-161.	0.3	82
32	Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. Journal of Neuroimmunology, 2006, 176, 198-215.	1.1	80
33	PQBP-1/Npw38, a Nuclear Protein Binding to the Polyglutamine Tract, Interacts with U5-15kD/dim1p via the Carboxyl-Terminal Domain. Biochemical and Biophysical Research Communications, 2000, 273, 592-595.	1.0	78
34	DJ-1 protects against oxidative damage by regulating the thioredoxin/ASK1 complex. Neuroscience Research, 2010, 67, 203-208.	1.0	77
35	Three-amino acid Extension Loop Homeodomain Proteins Meis2 and TGIF Differentially Regulate Transcription. Journal of Biological Chemistry, 2000, 275, 20734-20741.	1.6	75
36	Analysis of the promoter region of the rat D2 dopamine receptor gene. Biochemistry, 1992, 31, 8389-8396.	1.2	72

#	Article	IF	Citations
37	Cell cycle aberrations by Î±-synuclein over-expression and cyclin B immunoreactivity in Lewy bodies. Neurobiology of Aging, 2003, 24, 687-696.	1.5	72
38	Protection of nigral neurons by GDNF-engineered marrow cell transplantation. Neuroscience Research, 2001, 40, 315-323.	1.0	69
39	Translation of the intrinsically disordered protein Î±-synuclein is inhibited by a small molecule targeting its structured mRNA. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1457-1467.	3.3	69
40	The Parkinson's disease gene product DJ-1 modulates miR-221 to promote neuronal survival against oxidative stress. Redox Biology, 2018, 19, 62-73.	3.9	68
41	Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Annals of Neurology, 1992, 32, 776-781.	2.8	67
42	BDNF synthesis in spiral ganglion neurons is constitutive and CREB-dependent. Hearing Research, 2001, 156, 53-68.	0.9	67
43	Alternate 5â€² exons in the rat brain-derived neurotrophic factor gene: differential patterns of expression across brain regions. Molecular Brain Research, 1994, 26, 225-232.	2.5	65
44	Neuroprotective and Anti-inflammatory Properties of a Coffee Component in the MPTP Model of Parkinson's Disease. Neurotherapeutics, 2013, 10, 143-153.	2.1	65
45	Dopamine D1A Receptor Regulation of Phospholipase C Isoform. Journal of Biological Chemistry, 1996, 271, 19503-19508.	1.6	62
46	Cloning and Characterization of Murine Glial Cell-Derived Neurotrophic Factor Inducible Transcription Factor (MGIF). Journal of Neuroscience, 1997, 17, 8657-8666.	1.7	59
47	Dopamine receptor regulating factor, DRRF: A zinc finger transcription factor. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 7558-7563.	3.3	59
48	Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications. Journal of Neural Transmission, 1997, 104, 341-362.	1.4	57
49	Up-regulation of D1A dopamine receptor gene transcription by estrogen. Molecular and Cellular Endocrinology, 1999, 156, 151-157.	1.6	57
50	Apoptosis Signal-Regulating Kinase 1 Mediates MPTP Toxicity and Regulates Glial Activation. PLoS ONE, 2012, 7, e29935.	1.1	57
51	MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a. Journal of Neuroimmunology, 2015, 278, 185-189.	1.1	56
52	ZIC2 and Sp3 Repress Sp1-induced Activation of the HumanD Dopamine Receptor Gene. Journal of Biological Chemistry, 2000, 275, 38863-38869.	1.6	55
53	Human Polycomb protein 2 promotes Î±-synuclein aggregate formation through covalent SUMOylation. Brain Research, 2011, 1381, 78-89.	1.1	55
54	Transglutaminase 2: Biology, Relevance to Neurodegenerative Diseases and Therapeutic Implications. , 2012, 133, 392-410.		54

#	Article	IF	Citations
55	Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson's disease and DLB. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E12053-E12062.	3.3	54
56	MicroRNA-7 Promotes Glycolysis to Protect against 1-Methyl-4-phenylpyridinium-induced Cell Death. Journal of Biological Chemistry, 2015, 290, 12425-12434.	1.6	53
57	Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies. Annals of Clinical and Translational Neurology, 2016, 3, 769-780.	1.7	52
58	Spinal fluid CRF reduction in Alzheimer's disease. Neuropeptides, 1986, 8, 393-400.	0.9	51
59	Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Movement Disorders, 1994, 9, 463-465.	2.2	50
60	Î±-Synuclein phosphorylation as a therapeutic target in Parkinsonâ€™s disease. Reviews in the Neurosciences, 2012, 23, 191-8.	1.4	48
61	Dual Îºâ€agonist/Î¼â€antagonist opioid receptor modulation reduces levodopaâ€induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of <scp>P</scp>arkinson disease. Annals of Neurology, 2015, 77, 930-941.	2.8	45
62	Nucleic Acidâ€“Based Therapeutics for Parkinson's Disease. Neurotherapeutics, 2019, 16, 287-298.	2.1	45
63	Dopamine D _{1A} Receptors and Renin Release in Rat Juxtaglomerular Cells. Hypertension, 1997, 29, 962-968.	1.3	44
64	[3H]MK-801 binding in Alzheimer's disease. Neuroscience Letters, 1988, 93, 225-230.	1.0	42
65	Polar Amino Acid-Rich Sequences Bind to Polyglutamine Tracts. Biochemical and Biophysical Research Communications, 1998, 253, 16-20.	1.0	39
66	Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2018, 77, 139-148.	0.9	39
67	Therapeutics in the Pipeline Targeting<i>Î±</i>-Synuclein for Parkinson's Disease. Pharmacological Reviews, 2022, 74, 207-237.	7.1	39
68	Localization of CKII Î² subunits in Lewy bodies of Parkinson's disease. Journal of the Neurological Sciences, 2008, 266, 9-12.	0.3	38
69	Regulation of Signal Transduction by DJ-1. Advances in Experimental Medicine and Biology, 2017, 1037, 97-131.	0.8	38
70	Two Distinct Promoters Drive Transcription of the Human D1A Dopamine Receptor Gene. Journal of Biological Chemistry, 1996, 271, 25292-25299.	1.6	37
71	Sp Family Transcription Factors Regulate Expression of Rat D2Dopamine Receptor Gene. DNA and Cell Biology, 1998, 17, 471-479.	0.9	36
72	Alpha-synuclein in Parkinson's disease: Light from two new angles. Annals of Neurology, 2004, 55, 153-156.	2.8	32

#	Article	IF	Citations
73	Protection Against Acute MPTP-Induced Dopamine Depletion in Mice by Adenosine A1Agonist. Journal of Neurochemistry, 1993, 60, 768-771.	2.1	31
74	Synphilin-1 degradation by the ubiquitin-proteasome pathway and effects on cell survival. Journal of Neurochemistry, 2002, 83, 346-352.	2.1	31
75	Silica-coated magnetic nanoparticles impair proteasome activity and increase the formation of cytoplasmic inclusion bodies in vitro. Scientific Reports, 2016, 6, 29095.	1.6	30
76	Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and positron emission tomography. Brain Research, 1994, 635, 196-202.	1.1	29
77	Advances in Gene Therapy for Movement Disorders. Neurotherapeutics, 2008, 5, 260-269.	2.1	29
78	Transglutaminase 2 exacerbates Î±â€synuclein toxicity in mice and yeast. FASEB Journal, 2014, 28, 4280-4291.	0.2	29
79	Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinsonâ€™s disease. Neurochemistry International, 2012, 61, 899-906.	1.9	27
80	Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography. Journal of the Neurological Sciences, 1994, 123, 44-51.	0.3	25
81	Regulation of striatal dopamine receptors by corticosterone: an in vivo and in vitro study. Molecular Brain Research, 1999, 69, 281-285.	2.5	25
82	Apoptosis signal-regulating kinase 1 modulates the phenotype of Î±-synuclein transgenic mice. Neurobiology of Aging, 2015, 36, 519-526.	1.5	23
83	Role of striatal Î”FosB in <scp>l</scp> -Dopaâ€“induced dyskinesias of parkinsonian nonhuman primates. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 18664-18672.	3.3	22
84	MicroRNAs in neurodegenerative disorders. Cell Cycle, 2010, 9, 1717-1721.	1.3	21
85	Dopamine D-1 receptor agonist stimulation of prolactin secretion in man. Journal of Neural Transmission, 1988, 71, 159-163.	1.4	20
86	Up-regulation of D3 dopamine receptor mRNA by neuroleptics. , 1996, 23, 232-235.		20
87	AP-2Î² represses D1A dopamine receptor gene transcription in Neuro2a cells. Molecular Brain Research, 1999, 74, 208-216.	2.5	20
88	Localization of putative calcium-responsive regions in the rat BDNF gene. Molecular Brain Research, 1997, 50, 154-164.	2.5	18
89	Characterization of the 5â€² flanking region of the rat D3 dopamine receptor gene. Journal of Neurochemistry, 2001, 76, 1736-1744.	2.1	17
90	Increased Dynamics of Î±-Synuclein Fibrils by Î²-Synuclein Leads to Reduced Seeding and Cytotoxicity. Scientific Reports, 2019, 9, 17579.	1.6	17

#	Article	IF	Citations
91	Modulation of nigrostriatal dopaminergic transmission by antisense oligodeoxynucleotide against brain-derived neurotrophic factor. Neurochemical Research, 1998, 23, 525-532.	1.6	16
92	Tissue-Specific Promoter Usage in the D_{1A}Dopamine Receptor Gene in Brain and Kidney. DNA and Cell Biology, 1997, 16, 1267-1275.	0.9	15
93	IFN-Î²Gene Transfer into the Central Nervous System Using Bone Marrow Cells as a Delivery System. Journal of Interferon and Cytokine Research, 2002, 22, 783-791.	0.5	14
94	Brain-derived neurotrophic factor (BDNF) gene delivery into the CNS using bone marrow cells as vehicles in mice. Neuroscience Letters, 2004, 356, 215-219.	1.0	14
95	Transglutaminase 2 Depletion Attenuates Î±-Synuclein Mediated Toxicity in Mice. Neuroscience, 2020, 441, 58-64.	1.1	14
96	Developmental expression of the zinc finger transcription factor DRRF (dopamine receptor regulating) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.7	13
97	Complications of a trophic xenotransplant approach in parkinsonian monkeys. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 607-612.	2.5	13
98	Decrease in a proenkephalin peptide in cerebrospinal fluid in Huntington's disease and progressive supranuclear palsy. Brain Research, 1989, 479, 397-401.	1.1	12
99	Neural cell line-specific regulatory DNA cassettes harboring the murine D1A dopamine receptor promoter. Neuroscience Research, 1999, 34, 225-234.	1.0	11
100	MicroRNA-7 Protects Against Neurodegeneration Induced byÂÎ±-Synuclein PreformedÂFibrils in the Mouse Brain. Neurotherapeutics, 2021, 18, 2529-2540.	2.1	10
101	Silica-coated magnetic-nanoparticle-induced cytotoxicity is reduced in microglia by glutathione and citrate identified using integrated omics. Particle and Fibre Toxicology, 2021, 18, 42.	2.8	10
102	Apoptosis signal regulating kinase 1 deletion mitigates Î±-synuclein pre-formed fibril propagation in mice. Neurobiology of Aging, 2020, 85, 49-57.	1.5	9
103	Genomic organization and promoter characterization of the murine dopamine receptor regulating factor (DRRF) gene. Gene, 2003, 304, 193-199.	1.0	7
104	Interaction of nuclear factors from young and old rat brain regions with regulatory sequences of the D2 dopamine receptor gene promoter. Molecular Brain Research, 1997, 44, 113-124.	2.5	6
105	Letter from the Editor-in-Chief: Transitions. Neurotherapeutics, 2014, 11, 2.	2.1	6
106	Predicting the development of levodopa-induced dyskinesias. Neurology, 2014, 82, 1574-1575.	1.5	6
107	POU Transcription Factors Differentially Regulate the D1ADopamine Receptor Gene in Cultured Cells. Biochemical and Biophysical Research Communications, 1996, 222, 736-741.	1.0	4
108	Transcriptional auto-regulation of the dopamine receptor regulating factor (DRRF) gene. Molecular and Cellular Endocrinology, 2008, 289, 23-28.	1.6	4

#	Article	IF	Citations
109	Activation of the GDNF-inducible transcription factor (GIF) gene promoter by glucocorticoid and progesterone. Journal of Steroid Biochemistry and Molecular Biology, 2009, 115, 30-35.	1.2	4
110	Characterization of a corticotropin releasing hormone responsive region in the murine proopiomelanocortin gene. Molecular and Cellular Endocrinology, 1993, 97, 165-171.	1.6	3
111	In vivo regulation of glial cell line-derived neurotrophic factor-inducible transcription factor by kainic acid. Neuroscience, 1999, 94, 629-636.	1.1	3
112	Delivery of transgenically modified adult bone marrow cells to the rodent central nervous system. Expert Opinion on Biological Therapy, 2004, 4, 669-675.	1.4	2
113	Striatal Î”FosB gene suppression inhibits the development of abnormal involuntary movements induced by L-Dopa in rats. Gene Therapy, 2021, , .	2.3	2
114	Tumor suppressor PALB2 maintains redox and mitochondrial homeostasis in the brain and cooperates with ATG7/autophagy to suppress neurodegeneration. PLoS Genetics, 2022, 18, e1010138.	1.5	2
115	Letter From the Editor-in-Chief: Journal Transition in the Digital Age. Neurotherapeutics, 2017, 14, 831.	2.1	1
116	Rare genetic variants support mitochondrial dysfunction in Lewy body disorders. Neurology, 2015, 85, 2002-2003.	1.5	0
117	The Impact of Inclusion Formation on Cell Survival. , 2006, , 57-67.		0